A clinical trial is open so study Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. The triplet of carfilzomib, dexamethasone and daratumumab (KdD) is being compared to the doublet of carfilzomib and dexamethasone (Kd) to compare progression free survival for myeloma patients who have relapsed after 1-3 prior therapies.

This trial is expected to open soon at the Gabrail Cancer Research Center in Canton, Ohio.

To learn more, click here:

Carfilzomib/Dara/Dex Clinical Trial